Profusa AI Stock Analysis
Want to see PFSA full AI Analyst Report?
Profusa (PFSA) AI Stock Analysis
Profusa
(NASDAQ:PFSA)
PFSA scores near the bottom of the range, driven primarily by a high-risk, binary financial profile: no revenue in any reported period, a $25.7M trailing-twelve-month net loss, and roughly $12M of annual cash burn against a thin $7.8M equity cushion. Technicals reinforce the caution, with the stock trading far beneath all major moving averages and momentum still negative. Valuation offers no support given negative earnings and no dividend. Partial offsets include a materially improved capital structure — equity restored to positive territory, debt cut to $6.5M, and $6.14M of notes converted to preferred stock — plus confirmed Nasdaq compliance; however, continued reliance on small, dilutive secured convertible financings keeps shareholder dilution risk elevated.
Profusa (PFSA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.89M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.56M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.20
- Revenue Growth
- ―
- EPS Growth
- 96.27%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Profusa Business Overview & Revenue Model
Company Description
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor comp...
How the Company Makes Money
Profusa’s primary monetization model is expected to center on commercialization of its biosensing products and associated system components (e.g., implantable sensor units and external readers/wearables) and, where applicable, related services or sof...
Profusa Financial Statement Overview
Summary
Profusa is a pre-revenue, development-stage medical device company with zero reported revenue across all periods and widening losses, peaking at a $35.8M net loss in 2025 and $25.7M on a trailing-twelve-month basis. Cash flow is the weakest link: operating and free cash flow have been negative every year, with roughly $12M burned over the last twelve months and almost no capital spending to offset, meaning losses convert directly into cash outflows. The one bright spot is the balance sheet, where a recapitalization lifted shareholders' equity from deeply negative levels to a positive $7.8M, grew assets to $28.9M and cut debt to $6.5M (0.83x debt-to-equity). Even so, the equity cushion covers only a limited runway at the current burn rate, leaving the company reliant on continued external financing.
Income Statement
6Very NegativeBalance Sheet
27NegativeCash Flow
9Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -7,000 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -19.32M | -30.73M | -4.81M | -6.00M | -13.22M | -5.05M |
| Net Income | -25.73M | -35.82M | -9.23M | -10.28M | -20.22M | -10.31M |
Balance Sheet | ||||||
| Total Assets | 28.89M | 3.77M | 3.07M | 1.89M | 1.03M | 11.36M |
| Cash, Cash Equivalents and Short-Term Investments | 339.00K | 1.78M | 191.00K | 142.00K | 78.00K | 856.00K |
| Total Debt | 6.47M | 14.81M | 48.21M | 40.40M | 31.03M | 24.02M |
| Total Liabilities | 21.09M | 30.43M | 122.28M | 111.89M | 100.80M | 95.02M |
| Stockholders Equity | 7.79M | -26.66M | -119.20M | -110.00M | -99.77M | -83.66M |
Cash Flow | ||||||
| Free Cash Flow | -12.10M | -16.26M | -2.07M | -4.40M | -7.70M | -10.69M |
| Operating Cash Flow | -12.02M | -16.25M | -2.07M | -4.40M | -7.70M | -10.69M |
| Investing Cash Flow | 63.00K | -2.01M | 0 | -2,000 | 0 | 0 |
| Financing Cash Flow | 9.28M | 19.84M | 2.12M | 4.47M | 6.92M | 8.75M |
Profusa Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFSA, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 1.38, and below the 200-day MA of 52.72, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 30.99 is Neutral, neither overbought nor oversold. The STOCH value of 10.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFSA.
Profusa Risk Analysis
Profusa disclosed 86 risk factors in its most recent earnings report. Profusa reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksProfusa Peers Comparison
Overall Rating
MDT81Outperform
DXCM73Outperform
ABT67Neutral
SENS50Neutral
OWLT45Neutral
PFSA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $131.60B | 25.27 | 10.60% | 2.78% | 9.77% | 12.28% | |
| 73Outperform | $30.44B | 31.61 | 36.50% | ― | 13.03% | 40.88% | |
| 67Neutral | $186.10B | 39.96 | 9.11% | 2.35% | 10.00% | -66.06% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $597.11M | -4.72 | -186.15% | ― | 104.83% | -37.15% | |
| 45Neutral | $97.44M | -5.54 | -34.25% | ― | 13.74% | 78.29% | |
| 39Underperform | $245.71K | -0.00 | 138.72% | ― | ― | 96.27% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PFSA | Profusa, Inc. | 0.41 | -1347.35 | -99.97% | |
| ABT | Abbott Laboratories | 107.45 | -19.40 | -15.29% | |
| DXCM | Dexcom | 81.61 | 21.44 | 35.63% | |
| MDT | Medtronic | 102.88 | 5.31 | 5.45% | |
| SENS | Senseonics Holdings Inc. | 10.90 | 4.92 | 82.27% | |
| OWLT | Owlet Inc | 3.26 | -9.16 | -73.75% |
Profusa Corporate Events
Profusa Amends Promissory Note Conversion Pricing Terms
NeutralProfusa, Inc. and NorthView Sponsor I LLC amended a promissory note originally carrying principal of up to $2.5 million. On November 5, 2026, the Fourth Amendment set the conversion price at the greater of $0.20 or the Nasdaq closing price on the tra...
Profusa Issues Convertible Secured Note in Private Financing
NegativeOn October 15, 2026, Profusa issued a senior secured convertible promissory note to Ascent Partners Fund LLC with a principal amount of $769,230.77 for a purchase price of $700,000.00 under an existing securities purchase agreement. The note bears 7%...
Profusa Amends Convertible Notes and Financing Terms
NeutralOn October 4, 2026, Profusa amended two senior secured convertible promissory notes originally issued to Ascent Partners Fund LLC on April 2, 2026 and April 20, 2026, with maturities in 2027, altering key economic terms of the securities. The convers...
Profusa Adds Secured Convertible Debt Financing Agreement
NeutralOn September 16, 2026, Profusa completed an additional closing under its February 11, 2025 Securities Purchase Agreement with Ascent Partners Fund LLC, issuing a senior secured convertible promissory note with a principal amount of $384,615.38 for a...
Profusa Regains Nasdaq Compliance, Enters One-Year Monitoring
NeutralOn September 9, 2026, Profusa, Inc. received confirmation from Nasdaq that it had regained compliance with the Bid Price and Equity listing rules. The determination removes the immediate threat of delisting but places the company under a one-year Man...
Profusa Secures New Convertible Note Financing Agreement
NeutralOn September 1, 2026, Profusa, Inc. completed an additional closing under a February 11, 2025 securities purchase agreement and issued Ascent Partners Fund LLC a senior secured convertible promissory note with a principal amount of $329,670.33 for a...
Profusa Confirms Continued Compliance With Nasdaq Listing Standards
PositiveOn August 26, 2026, Profusa disclosed that Nasdaq’s Listing Qualifications Department had initially notified the company that its recent 1-for-4 reverse stock split left it with fewer than the 500,000 publicly held shares required under Nasdaq Listin...
Profusa Strengthens Capital Structure Through Debt-to-Equity Exchange
PositiveOn August 12, 2026, Profusa entered into a fifth amendment to its 2025 securities purchase agreement with Ascent Partners Fund, updating the amendment effective date, adding a new optional note form and resetting the exercise price of an existing war...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
